Oral Semaglutide
OASIS 2
Novo Nordisk · Phase 3 · Completed · Enrollment 201
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| oral semaglutide 50 mg once daily | 34 participants | 20 participants | 22 participants | n/r | 0 |
| oral semaglutide placebo once daily | 5 participants | 2 participants | 6 participants | n/r | 0 |
A count stays a count. This page does not turn a count into a percent.